Human Genome Epidemiology Literature Finder
|
Records 1 - 10 (of 10 Records) |
| Query Trace: Leukopenia and Egfr[original query] |
|---|
| Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
| Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer chemotherapy and pharmacology 2018 May . Imai Hisao, Minemura Hiroyuki, Sugiyama Tomohide, Yamada Yutaka, Kaira Kyoichi, Kanazawa Kenya, Kasai Takashi, Kaburagi Takayuki, Minato Koichi, |
| Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study. Lung cancer (Amsterdam, Netherlands) 2019 6 133 23-31. Xu Lisheng, Qi Qian, Zhang Yan, Cui Jiadong, Liu Ruijuan, Li |
| Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ?75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational lung cancer research 2020 7 9 (3): 459-470. Kozuki Toshiyuki, Nogami Naoyuki, Hataji Osamu, Tsunezuka Yoshio, Seki Nobuhiko, Harada Toshiyuki, Fujimoto Nobukazu, Bessho Akihiro, Takamura Kei, Takahashi Kazuhisa, Satouchi Miyako, Kato Terufumi, Shukuya Takehito, Yamashita Natsumi, Okamoto Hiroaki, Shinkai Tetsu, |
| First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in oncology 2021 4 11 598265. Wu Qiang, Luo Wuxia, Li Wen, Wang Ting, Huang Lin, Xu Fe |
| Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial. Translational lung cancer research 2022 9 11 (8): 1606-1618. Park Cheol-Kyu, Oh Hyung-Joo, Yoo Seung Soo, Lee Shin Yup, Lee Sang Hoon, Kim Eun Young, Lee Sung Yong, Choi Juwhan, Lee Min Ki, Kim Mi-Hyun, Jang Tae Won, Chung Chaeuk, Oh In-Jae, Kim Young-Ch |
| PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. Journal of cancer research and clinical oncology 2022 7 148 (12): 3557-3566. Zhu Yixiang, Zhang Ye, Hu Xingsheng, Wang Mingzhao, Wang Hongyu, Liu Yut |
| Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Feb . Shi Yuankai, Zhao Yanqiu, Yang Sheng, Zhou Jianying, Zhang Liangming, Chen Gongyan, Fang Jian, Zhu Bo, Li Xingya, Shu Yongqian, Shi Jianhua, Zheng Rongsheng, Wang Donglin, Yu Huiqing, Huang Jianan, Zhuang Zhixiang, Wu Gang, Zhang Longzhen, Guo Zhongliang, Greco Michael, Li Xiao, Zhang |
| First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study. Annals of medicine 2023 8 55 (2): 2243967. Yahua Wu, Bin Du, Chengliu Lv, Xiaohui Ji, Yanqin Lan, Na Yao, Yingjiao Zhu, Jinhuo L |
| A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
- Page last reviewed:Feb 1, 2024
- Content source: